S. Rodgers

发表

Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants.

K. Hayat, E. Sheridan, S. Reeder, 1992, European journal of cancer.

A mutant allele of MRE11 found in mismatch repair-deficient tumor cells suppresses the cellular response to DNA replication fork stress in a dominant negative manner.

M. Meuth, G. Phear, S. Rodgers, 2008, Molecular biology of the cell.

Clinical heterogeneity within xeroderma pigmentosum associated with mutations in the DNA repair and transcription gene ERCC3.

R. Scott, J. Hoeijmakers, W. Vermeulen, 1994, American journal of human genetics.

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase

M. Wangpaichitr, N. Savaraj, Chunjing Wu, 2012, British Journal of Cancer.

Changes in the phenotypic characteristics of eosinophils from patients receiving recombinant human interleukin‐2 (rhIL‐2) therapy

R. Rees, B. Hancock, S. Rodgers, 1994, British journal of haematology.

Malignant melanoma and renal cell carcinoma: immunological and haematological effects of recombinant human interleukin-2.

R. Rees, K. Hayat, E. Sheridan, 1991, European journal of cancer.

Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma.

R. Rees, M. Gore, J. Kirkwood, 1999, Human gene therapy.

An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma.

R. Rees, R. Start, A. Murray, 1997, British Journal of Cancer.

MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue.

R. Rees, R. Coleman, J. Tidy, 1998, British Journal of Cancer.

Infrequent expression of the MAGE gene family in uveal melanomas

R. Rees, S. Leyvraz, F. Brasseur, 1996, International journal of cancer.